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O r i g i n a l  P a p e r
H i g h  D o s e  E p i r u b i c i n  i s  E f f e c t i v e  i n  M e a s u r a b l e  
M e t a s t a t i c  P r o s t a t e  C a n c e r :  a  P h a s e  I I  S t u d y  o f
t h e  E O R T C  G e n i t o u r i n a r y  G r o u p
M. Brausi, W.G. Jones, S.D. Fossa, P.H.M. de Mulder, J.-P. Droz, 
M.-A. Lentz, M. van Glabbeke, A. Pawinski and members of the 
EORTC Genitourinary Cancer Research Group
39 hormonenresistant prostate cancer patients with bidimensionaily measurable metastatic lesions were given 
epirubicin 100 mg/m2 intravenously every 3 weeks. One patient was ineligible and excluded from analyses. 
According to WHO criteria, 9 patients (24%) had a partial response, 16 patients (42%) had stable disease (including
3 patients (8%) with a partial response not confirmed 1 month later), 11 patients (29%) had progressive disease, 
and in 2 patients (5%) response was not evaluated. Toxicity was as expected. Fifty-five per cent of patients had 
WHO grade 3/4 toxicity for white blood cells, and 3% of patients grade 3 toxicity for platelets. Other toxicities 
included nausea and vomiting, mucositis and alopecia* 2 patients with pre-existing cardiac disease developed 
cardiotoxicity (1 grade 2, 1 grade 3). An attempt was made to correlate response with prostate specific antigen 
(PSA) measurements. A positive trend was seen, but 2 non-responding patients showed a >  50% decrease in 
value.
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INTRODUCTION
The o v e ra l l  outlook for patients with metastatic prostate 
cancer who are, or who become, resistant to hormonal therapies 
is poor, with a median survival of 44 weeks [1]. Survival is 
considerably shorter for those who develop soft tissue métast­
asés. Unfortunately 5 chemotherapy has so far proved to be of 
little value in prostate cancer, and cannot yet be accepted as 
forming part of the standard management of this disease [2]. No 
single cytotoxic drug or combination of drugs has been shown to 
improve survival [2-5].
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The EORTC Genitourinary Cancer Cooperadve Group has 
undertaken a number of phase II chemotherapy studies in 
the hope of identifying active agents [6-9] and has also been 
concerned with the need to objectively assess response in phase
II studies. A policy of using only bidimensionaily measurable 
soft tissue and visceral lesions has been employed, since the 
determination of response in (the commoner) bone lesions is 
currently impossible [10]. In an attempt to identify other useful 
parameters by which response can be assessed, and to evaluate 
whether serial values of serum prostate specific antigen (PSA) 
correlate with objective response, a scientific “side study” was 
proposed when the study reported here was initiated in 1989.
The rationale for the selection of epirubicin at high dose was 
based on observations made during a previous study performed 
by the group (protocol 30841) of low dose epirubicin at the rate 
of 12 mg/m2 weekly. Although the overall objective remission 
rate (complete and partial response: CR + PR) in that study was 
only 12%, 1 patient achieved a CR and 2 had a PR with marker 
lesion CR (i.e. the marker lesions vanished, but there was 
evidence of unmeasurable disease elsewhere). There was good 
subjective improvement in those patients who responded to this 
low dose treatment and doubts were raised as to whether or not 
the intensity of the treatment was too low. It was proposed that
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the drug should be tested again at a more conventional dose and 
schedule. On the basis of the experience of members of the 
group with epirubicin, at a dose intensity of 100 mg/m2 every 3 
weeks, in treating patients with advanced bladder cancer, this 
schedule was adopted.
PATIENTS AND METHODS
A phase II study was performed. Only patients with histologi­
cally proven carcinoma of the prostate with evidence of disease 
progression prior to entry into the study were accepted. All 
patients had to have bidimensionaily measurable disease in the 
form of métastasés to lung, superficial lymph nodes, skin 
and subcutaneous tissues and lymph nodes (if measurable by 
computed tomography (CT) scan) in the mediastinum, retr operi- 
toneum or pelvis. The initial diameters of such nodes had to be 
greater than 2.5 cm to allow reliable measurements during 
follow-up. Liver métastasés were also accepted provided they 
could be measured by either abdominal ultrasound or CT 
scanning, again with an initial diameter >  2.5 cm. All patients 
had to have undergone prior hormone manipulation, but additive 
hormonal therapy which was failing had to be stopped at least 1 
day before the protocol therapy was started. For those patients 
in whom an accelerated relapse was feared when exogenous 
hormones were to be stopped, the study protocol suggested that 
the patient should be considered for an orchidectomy. It was 
also suggested that a reasonable period of time elapsed following 
hormone withdrawal before the study drug was commenced, in 
case a further response was seen. Previous cytotoxic drug therapy 
disqualified the patient, as did the presence of concomitant 
malignancy, except for basal cell skin cancer. Previous radio­
therapy did not disqualify the patient from entry provided there 
was one unirradiated indicator lesion.
Patients had to be under the age of 75 years, have an expected 
survival of more than 60 days and a WHO performance status 
[11] of 2 or less. The initial full blood count had to show a 
white blood cell count greater than 4 X 109/1, and platelets 
>  100 X 109/1, unless a depressed count could be proved to be 
due to tumour invasion of the bone marrow* Adequate renal 
function as evidenced by a serum creatinine of less than 
120 fxmol/1 was required, as too was adequate liver function with 
serum bilirubin less than 20 fxmol/1.
If there was expected difficulty with follow-up for any reason, 
or the patient had medical or social conditions preventing the 
optimal application of the drug, the patient was ineligible for the 
study. Therefore, since epirubicin has potential cardio toxic side- 
effects, this precluded the admission of patients with congestive 
cardiac failure, significant cardiac arrhythmias, complete bundle 
branch block, recent myocardial infarction or uncontolled 
hypertension.
The aim of the study was to determine the objective tumour 
response rates and duration of response produced by epirubicin 
when given in a dose of 100 mg/m2 by bolus intravenous injection 
with a saline flush-through. The drug was administered every
3 weeks and treatment continued until the development of 
progressive disease or the stipulated maximum cumulative dose 
of 1 g/m2 was achieved. At this dose level, treatment could be 
continued at the discretion of the investigator, provided that a 
PR or a good no change (NC) category response was evident and 
the treatment was being well tolerated by the patient, while 
recognising the increased risk of cardiotoxicity.
Treatment was withheld if the total white blood cell count was 
<  4 x 109/1, the granulocyte count <  2 x  109/1 or the platelet 
count <  100 x 109/1. Treatment was postponed for a maximum
of 2 weeks if these levels were not reached after which the patient 
went off study. If the treatment had to be delayed because of a 
suppressed count, a dose reduction to 75 mg/m2 was required 
for the next and subsequent courses of treatment. This dose 
reduction was also made for individual courses when the nadir 
total white blood cell count was <  1 x 109/1, the granulocyte 
count <0.5 X 109/1 or platelet count <50 x 109/1. The nadir 
count was taken as occurring on day 14 of each cycle.
If the serum bilirubin rose to between 30 and 50 |xmol/l then 
the dose was reduced to 50%. Above the upper limit stated the 
dose was withheld. Any evidence of cardiac or lung toxicity, an 
allergic reaction or any other toxicity likely to be life-threatening 
and thought to be due to the investigational drug prompted the 
patient to go off-study.
At least two courses of the protocol treatment were to be 
given. Patients not receiving two courses could not be evaluated 
for response unless they had rapidly progressive disease, when 
the response was recorded as progressive disease (PD). Patients 
with an objective response (CR or PR) or NC with a stable 
performance status were maintained on treatment until objective 
disease progression or significant toxicity developed. If a CR was 
achieved, treatment was to continue for at least three more 
courses if toxicity allowed.
Ancillary treatments, excluding hormones, could be given as 
medically indicated, but no hepatotoxic drugs were allowed. 
Radiotherapy could be given concomitantly provided that the 
treatment did not include the indicator lesion. Treatment could 
be interrupted or stopped at the discretion of the investigator or 
at the request of the patient. Patients had to give informed 
consent according to the rules and regulations of the individual 
participation institutions. Permission to proceed with the study 
had to be obtained from the institutional Ethical Committee.
Pretreatment studies included clinical history, physical exam­
ination, assessment of performance status, measurement of 
palpable disease, height, weight, full blood count, biochemical 
profile, tests of liver and renal function, chest X-ray, ECG 
(electrocardiogram) and CT scanning and ultrasonography as 
means of measuring the indicator lesions. Follow-up investi­
gations included the above prior to each dose of epirubicin and 
an assessment of response was made after every two doses. The 
WHO criteria for response were used [11]. Tumour size was 
defined as the product of the two largest perpendicular diameters 
of the lesions. CR was defined as the complete disappearance of 
all known disease determined by two observations not less than
4 weeks apart. PR was a 50% or more decrease in total tumour 
size of the lesion(s) determined by two observations not less than
4 weeks apart. In addition, there could be no new lesions 
appearing or progression of any lesion. NC was defined as >50% 
decrease in total tumour size or a >  25% increase in size of one 
or more of the measurable lesions was demonstrated. PD was 
defined as a 25% or more increase in the size of any one or more 
measurable lesions, or the appearance of a new lesion. Early 
death was defined as death occurring during the first 4 weeks 
due to tumour progression and early toxic death as death 
occurring in the first 4 weeks due to drug toxicity.
Extramural review of all the study forms was undertaken by 
the study coordinator (WGJ), in conjunction with the data 
manager, statistician and research fellow.
RESULTS
The study was initiated on 28 April 1989 and closed on 
26 February 1992. 39 patients were entered. They have all now 
gone off-study and the study forms have been evaluated by the
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Table L  Best overall response-—38 eligible patients
Response No. of patients Percentage
Partial response 9 24
No change* 16 42
Progressive disease 11 29
Not evaluated 2 5
Total no. of patients 38 100
Overall response rate (all patients) 24% (11.4-40.2)1
Overall response rate (evaluable patients) 25% (12.1-42.2)t
* Including 3 patients in partial response, not confirmed by a second 
measurement, f  Figures in parentheses = 95% confidence interval.
Table 2. Response by type of marker lesion
Measurable Response Non- Total
lesion CR PR NC PD evaluable
Lymph nodes 12 10 9 8 3 42
Lung 0 0 3 3 1 7
Liver 3 8 8 1 2 22
Skin 0 0 0 1 0 1
Subcutaneous 0 1 1 1 0 3
CR, complete response; PR, partial response; NC, no change; PD, 
progressive disease.
study coordinator. One patient was ineligible by virtue of not 
having a bidimensionaily measurable marker lesion. He has been 
excluded from analyses, leaving 38 patients fully evaluable for 
response, time to progression and toxicity analyses. All the 
patients had objective evidence of progression at the start of the 
study and met the inclusion criteria as detailed above. These 
patients came from 14 institutions in Europe. The mean age of 
the patients was 63 years (range 45-75). 27 of the patients had 
undergone an orchidectomy at some time prior to study entry
Table 3. Haematological toxicity (nadir values)—38 eligible
patients
% Toxicity
WHO grade % Grade % Grade
0 1 2 3 4 1-4 3-4
White blood cells 2 3 12 19 2 95 55
Neutrophils* 9 2 6 6 6 69 41
Platelets 34 3 0 1 0 11 3
Haemoglobin 12 12 8 6 0 68 16
* Nine missing values.
Table 4. Distribution of nadirs (day 14)
Blood parameter Median value Limits Measure
White blood cells 1.9 0.60-4.80 109/1
N eutrophils 1.09 0.05-5.20 109/1
Platelets 187 37-413 109/1
Haemoglobin 6.15 4.30-8.60 mmol/1
Table 5. N  on-haematological side-effects—38 patients evaluable
for toxicity
Toxicity (worst) by WHO
grade % Grade
0 1 2 3 4 3-4
Nausea/vomiting 9 13 9 5 2 18
Diarrhoea 31 6 1 0 0 0
Mucositis 29 5 2 2 0 5
Phlebitis 36 0 1 1 0 3
Cutaneous reaction 36 1 1 0 0 0
Allergy 38 0 0 0 0 0
Liver toxicity* 32 0 1 0 0 0
Renal toxicity! 36 0 0 0 0 0
Pulmonary toxicity^ 36 0 1 0 0 0
Cardiotoxicity§ 33 0 1 2 0 6
Neurotoxicity 32 4 2 0 0 0
Alopecia 9 7 9 12 1 34
Drug fever] 1 30 3 4 0 0 0
Hypotension! 36 0 0 0 0 0
Infection 34 2 1. 1 0 3
Haemorrhage 36 2 0 0 0 0
Ototoxicity^] 37 0 0 0 0 0
* Five missing values, f  Two missing values. !  One patient had pre­
existing pulmonary insufficiency. § Two patients had pre-existing 
cardiac disease. || One patient had a pre-existing fever. H One missing 
value.
and the other 11 had received additive hormone treatment. 15 
patients had received prior radiotherapy treatment.
Response
The overall response rates are shown in Table 1. 9 patients 
(24%) achieved a PR? among whom 1 patient had an unexplained 
dose reduction during part of the treatment. Another 3 patients 
(8%) were categorised as having NC since the PR was not 
confirmed 4 weeks after first documentation. 2 patients were 
excluded from the evaluation of response because of the follow­
ing reasons: a different method of imaging was used to measure 
objectively the indicator lesion from the original (ultrasound/ 
CT), and this was not allowed by the study protocol; the response 
was never assessed after the second course. The response by 
marker lesion is shown in Table 2 (patients often had more than 
one marker lesion). Fifteen CRs were evaluated in marker 
lesions, but since these patients also had other lesions which did 
not completely respond, the overall response rate had to be 
classified as PR. The median duration of response (PR) was 
computed by an actuarial method (Kaplan-Meier) and found to 
be 28 weeks (range 20-90).
Toxicity
All 38 patients were evaluable for toxicity. Haematological 
toxicity was as expected with approximately 50% of patients 
suffering grade III/IV WHO toxicity for white blood cells and 
neutrophils as can be seen in Table 3. Nadir values are shown 
in Table 4. Non-haematological side-effects reported during 
treatment are shown in Table 5. These were much as expected 
with 18% grade III/VI nausea and vomiting and 34% alopecia 
grade III/IV. 2 patients with pre-existing cardiovascular disease 
developed cardio toxicity. One patient developed myocardial 
ischaemia during his fourth and last cycle, and a second patient 
developed angina pectoris with decreasing ejection fraction
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Table 6 . Comparison o f objective tumour response and prostate specific antigen (PSA) response (25
eligible patients with at least two P SA  measurements during treatment)




Range of PSA 
changes 
% of initial value
Total
2= 50% decrease 5 1 1 1 0 0.2-44 8
< 50% decrease 1 3 0 2 Ì 59-93 7
Increase 0 0 4 5 1 108-670 10
Total 6 4 5 8 2 — 25
* Partial remission without confirmation of the response at or after 8 weeks.
during the second cycle with an overall response of NC. On the 
whole, treatment was well tolerated although 4 patients went 
off-study due to toxicity for the following reasons: (a) sudden 
deterioration in general condition with progressive pain and 
general malaise after five cycles, having achieved a PR remission; 
(b) nausea and vomiting grade IV after a total of three cycles in 
PR; (c) reduced blood counts, phlebitis, diarrhoea, nausea and 
vomiting, the patient going off-study after five cycles with a NC 
category of response; (d) cardiotoxicity with a decreasing ejection 
fraction on echocardiography after two cycles (NC response) in 
the face of pre-existing heart disease.
2 patients refused to continue treatment and 2 patients went 
off-study after reaching the maximum cumulative dose (1 g/m2).
Correlation o f response with PSA estimations
25 of the eligible patients had at least two serum PSA 
investigations performed during the study period. The PSA 
response in terms of a ^  50% decrease, a <  50% decrease or 
an increased value was compared with the objective tumour 
responses observed and is shown in Table 6 . From this it can be 
seen that there is a general trend towards a positive correlation, 
although it must be pointed out that 2 patients with NC or PD 
responses had a >  50% decrease in PSA estimations. It is 
generally felt that on the basis of the data available, no further 
comment can be made except that this phenomenon needs to be 
validated in the next study performed by the group.
DISCUSSION
This phase II study of epirubicin (given at a dose of 
100 mg/m2 every 3 weeks) reveals that this agent has good 
antitumour activity when used at this dose in patients with 
progressive measurable metastatic disease from prostate cancer. 
It is recognised that this highly selected patient population with 
soft tissue/visceral métastasés is not typical of the great majority 
of prostatic cancer patients with metastatic disease. However, in 
those patients in which a response was observed, there was 
generally a decrease in symptoms and an improvement in 
performance status. Twenty-four per cent of patients had a 
confirmed PR, 3 further patients had a PR which was not 
confirmed 1 month later. The median duration of PR was 28 
weeks (range 20-90). Patients in the NC category had a mean 
duration of response of approximately half this duration (15 
weeks). This response rate is much improved to that reported 
by us in 1987 [8], when a low dose weekly regime had been used, 
but the dose intensity is almost three times greater. Toxicity was 
as expected but manageable. 2 patients of the 38 evaluable 
developed cardiac problems (1 fatal) despite the exclusion of 
patients with prior cardiac conditions at study entry. The 
response rate and manageable toxicity suggest that this treatment
is a useful addition to the pitifully small list of active agents in 
the treatment of this disease.
In an attempt to validate the suggestion that PSA may become 
a useful way of monitoring response in patients undergoing 
phase II chemotherapy studies in prostate cancer, a trend 
was seen to support this suggestion, although further work is 
necessary in order to validate this. PSA has become a very useful 
tool for the clinician managing prostate cancer [12], though the 
reliability of PSA and serum acid phosphatase (SAP) measure­
ments to monitor response in patients with bidimensionaily 
measurable hormone refractory prostatic carcinoma remains to 
be proved [13]. It may be that the natural biology of prostate 
cancer is such that the expression of PSA might be switched off 
in patients developing soft tissue metastatic disease. Soft tissue 
métastasés are usually detected in only approximately 10-15% 
of patients with métastasés in any case. Therefore, these patients 
may not be representative of the metastatic prostate cancer 
patient population with bone métastasés predominating. This 
leads us back to the original question as to whether or not such 
indicator lesions as soft tissue lesions can be used to assess 
response in this patient population. The EORTC Genitourinary 
Group will attempt to assess response in subsequent studies 
using a variety of objective, biochemical and subjective criteria 
including quality of life instruments. The role of PSA as a 
potential measure of response will be investigated further.
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